Israeli Scientists Achieve Breakthrough in Schizophrenia Treatment

Israeli researchers have made significant strides in treating schizophrenia, demonstrating immediate improvements in brain function during a recent trial. Conducted at the Rambam Health Care Campus in Haifa, the study involved administering hallucinogens to two monkeys, followed by treatment using electrical impulses through a technique known as Deep Brain Stimulation (DBS).

The goal of this innovative approach is to reconnect areas of the brain that are often “disconnected,” which is a major factor contributing to schizophrenia. Lead researcher Nir Asch, who works in the psychiatric department under the mentorship of Professor Hagai Bergman, a noted DBS pioneer and recipient of the 2024 Israel Prize, explained the mechanics of the brain as a “prediction machine.” He stated, “The brain tries to predict what will happen… It asks, ‘What is the situation? What is happening around me?’”

For individuals suffering from schizophrenia, this predictive process falters. Their internal models become rigid, failing to adapt to changes in their external environment. “They are kind of stuck in their own model,” Asch noted. “The input is there, but they don’t relate.”

During the trial, the monkeys exhibited chaotic and dissociated behavior after being administered hallucinogens—reminiscent of symptoms seen in schizophrenia patients. Following the DBS treatment, the researchers observed remarkable results. The treatment seemingly corrected the disconnect, allowing the monkeys to revert to their baseline mental state. Asch remarked, “The cognitive inflexibility was cured. The monkeys returned to the levels of when they were healthy, and they were also much less chaotic.”

Following the success of this initial study, the research team is now preparing to advance the trial to human subjects. Asch emphasized the importance of moving forward, stating, “Because the study was successfully performed on non-human primates, whose brains are remarkably similar to those of humans, we’re already meeting to discuss the best way to move forward.”

Asch, who combines his research with clinical practice, expressed a deep motivation to enhance treatment options for patients. “Seeing the patients and witnessing the burden on their families gives me a lot of motivation to take it to the next step. It can be very frustrating as a doctor when we don’t have great treatments. If we can add more tools that are effective and pave the way to recovery, then it would be so wonderful.”

The implications of this research could be transformative, offering new hope for individuals affected by schizophrenia and their families. As the team progresses towards human trials, the neuroscience community and patients alike will be watching closely for further developments.